Skip to main content
Premium Trial:

Request an Annual Quote

Rigaku Creates Contract Protein Crystallography Subsidiary

NEW YORK, Nov. 25 (GenomeWeb News) - Rigaku of Tokyo, Japan, said today that it has converted its X-ray crystallography contract services and consulting division into an independent, wholly owned subsidiary called PharmAxess.

PharmAxess is capitalized at 30 million yen ($274,000) and located in Harima Science Garden City, home to Japan's SPring-8 (SP-8) synchrotron. The company will offer contract protein crystallography services by leasing time at SP-8 or using Rigaku's in-house HomeLab LightSource X-ray diffraction systems.

Contract services will be based upon milestone payments. Rigaku said the subsidiary should see sales of 200 million yen ($1.8 million) in 2004.

Yukiteru Katsube, former head of the Institute for Protein Research at Osaka University, will become president and CEO of PharmAxess, which will initially employ 10 staffers.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.